[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100625270":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":33,"centralContacts":34,"locations":40,"responsibleParty":61,"collaborators":33,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":66,"sex":72,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":33,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":86,"whyStopped":33,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Izmir City Hospital","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"SiLAc Group","EXPERIMENTAL","Participants assigned to this arm will receive Silac (laser ablation) treatment for primary pilonidal sinus disease.",[13],"Procedure: SiLac (Laser Ablation)",{"label":15,"type":10,"description":16,"interventionNames":17},"Phenol Group","Participants assigned to this arm will receive phenol application treatment for primary pilonidal sinus disease.",[18],"Procedure: Phenol Application",[20,27],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"PROCEDURE","SiLac (Laser Ablation)","Laser ablation of the pilonidal sinus tract performed according to the study protocol.",[9],[26],"SiLac",{"type":21,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"Phenol Application","Chemical ablation with phenol performed according to the study protocol.",[15],[32],"Phenol",null,[35],{"name":36,"role":37,"phone":38,"phoneExt":33,"email":39},"Mehmet A Ugur","CONTACT","+905345839945","mehmet.alperen.ugur@gmail.com",[41],{"facility":5,"status":33,"city":42,"state":43,"zip":44,"country":45,"countryCode":33,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Izmir","İzmir","35540","Turkey (Türkiye)",{"type":47,"coordinates":48},"Point",[49,50],27.13838,38.41273,{"lat":50,"lon":49},[53,54,58],{"name":36,"role":37,"phone":38,"phoneExt":33,"email":39},{"name":55,"role":37,"phone":56,"phoneExt":33,"email":57},"Halil Yıldız","+905416572995","drhalilyildiz@gmail.com",{"name":59,"role":60,"phone":33,"phoneExt":33,"email":33},"Mehmet A Uğur","PRINCIPAL_INVESTIGATOR",{"type":60,"investigatorFullName":62,"investigatorTitle":63,"investigatorAffiliation":5,"oldNameTitle":33,"oldOrganization":33},"Mehmet Alperen Uğur","M.D, General Surgeon","100625270","silac-versus-phenol-for-the-treatment-of-pilonidal-sinus-disease-a-randomized-controlled-trial-100625270",false,"NCT07420452","Silac Versus Phenol for the Treatment of Pilonidal Sinus Disease: A Randomized Controlled Trial","Comparison of Silac and Phenol Treatments in Primary Pilonidal Sinus Disease: A Prospective Randomized Controlled Trial With 6-Month Follow-up","SILPHEN26","Inclusion Criteria:\n\n* Age between 18 and 64 years\n* Diagnosis of primary pilonidal sinus disease\n* Maximum of three sinus openings (pits)\n* History of no more than two previous abscess episodes\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Recurrent or previously operated pilonidal sinus disease\n* More than three sinus openings\n* More than two previous abscess episodes\n* Acute abscess requiring emergency drainage at presentation\n* Presence of significant uncontrolled comorbidities\n* Pregnancy\n* Inability to comply with follow-up","ALL","18 Years","64 Years",{"count":76,"type":77},200,"ESTIMATED","INTERVENTIONAL",[80],"NA","Pilonidal sinus disease is a common condition affecting young adults and is associated with pain, infection, and reduced quality of life. Various minimally invasive treatment options have been developed to reduce recurrence and improve recovery time. Among these methods, Silac (laser ablation) and phenol application are frequently used techniques.\n\nThe aim of this prospective randomized controlled trial is to compare the effectiveness and safety of Silac and phenol treatments in patients with primary pilonidal sinus disease. Eligible patients will be randomly assigned to receive either Silac or phenol treatment. The primary outcome of the study is recurrence rate. Secondary outcomes include postoperative pain, healing time, time to return to work, patient satisfaction, and treatment cost.\n\nPatient recruitment is planned over a 6-month period, and each participant will be followed for 6 months after treatment. The total study duration will be 12 months. The results of this study are expected to provide evidence to guide the selection of minimally invasive treatment options for primary pilonidal sinus disease.",[83],"Pilonidal Sinus Disease",[83,26,32,85],"Sacrococcygeal Pilonidal Sinus","NOT_YET_RECRUITING","2026-02-12",{"date":89,"type":90},"2026-02-19","ACTUAL",{"date":87,"type":77},{"date":93,"type":77},"2026-12-31",{"name":5,"class":6},1]